Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.

The Journal of investigative dermatology - 1 Dec 2016

Li Katherine, Huang C Chris, Randazzo Bruce, Li Shu, Szapary Philippe, Curran Mark, Campbell Kim, Brodmerkel Carrie

Abstract excerpt

Several small studies suggest that the presence of the human leukocyte antigen (HLA)-Cw6 (C*06:02) allele may be a predictor of improved response to ustekinumab. This study was designed to assess the association of the HLA-C*06:02 allele with response to ustekinumab in large cohorts of patients from the phase 3 studies of ustekinumab in moderate-to-severe psoriasis. In this retrospective study, both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analysis of Variance
Share to Confidence Intervals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to HLA-C Antigens

Share to Interleukin-23

Share to Molecular Targeted Therapy

Share to Psoriasis

Source

Identifiers

PMID: 27476722
DOI: 10.1016/j.jid.2016.06.631

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.PMID 27476722Read ↗

Association ofHLA-C*06:02Status With Differential Response to Ustekinumab in Patients With PsoriasisSemantic proximity Read ↗

Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.Semantic proximity Read ↗

HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-upSemantic proximity Read ↗

HLA-C*06 and psoriasis: susceptibility, phenotype, course and response to treatment.Semantic proximity Read ↗

Association between HLA-Cw*0602 polymorphism and psoriasis risk: a meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of psoriasis:<i>HLA-Cw6</i>but not<i>LCE3B/3C</i>deletion nor<i>TNFAIP3</i>polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumabSemantic proximity Read ↗

Pharmacogenetics Update on Biologic Therapy in PsoriasisSemantic proximity Read ↗

The HLA-Cw12 Allele Is an Important Susceptibility Allele for Psoriasis and Is Associated with Resistant Psoriasis in the Turkish PopulationSemantic proximity Read ↗

Distinct Clinical Differences Between HLA-Cw*0602 Positive and Negative Psoriasis Patients – An Analysis of 1019 HLA-C- and HLA-B-Typed PatientsSemantic proximity Read ↗

IL12B, IL23A, IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment.Semantic proximity Read ↗

HLA-Cw1 and Psoriasis.Semantic proximity Read ↗

Allele-specific cytokine responses at the HLA-C locus: implications for psoriasis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.